Looking for pain relief options for your IUD placement? Swedish gynecologists just tested this local anesthetic and it seems to work.
The post Bulletin: Pain Relief for IUD Insertion That Works appeared first on Medical News Bulletin.
Interventional glaucoma is a topic that is often in the eye care news, but it is not always clear what the term means.
Now, there is more clarity, thanks to a new consensus treatment protocol developed by a group of expert clinicians, the Interventional Glaucoma Working Group. The group achieved unanimous consensus on a new approach to glaucoma treatment that is much less glaucoma drop-centric than typical management protocols (Funke, et al.).
For starters, the consensus states that drops are considered as bridge and supplemental therapy, rather than primary therapy. This interventional
VIENNA — In a phase 2 study, SAR402663 gene therapy for wet age-related macular degeneration showed positive efficacy and safety interim results with a single in-office intravitreal injection.
With a medium dose of SAR402663, there was a 97% reduction in treatment burden, with more than 90% of patients not needing supplemental anti-VEGF injections, Arshad M. Khanani, MD, MA, FASRS, said at the Euretina congress.
Researchers have observed positive functional and anatomic results with the therapy, and the safety profile appears good.
SAR402663 (Sanofi) is an investigational AAV2 gene therapy
I had not seen measles until 1989, when I was a fellow at The Children’s Hospital of Philadelphia. It was the beginning of the first major resurgence of measles in the United States during the vaccine era.
Philadelphia went on to experience a 2-year outbreak that claimed the lives of nine children. (If you want to understand the human side of that story, read Paul Offit’s 2015 book Bad Faith.) Between 1989 and 1991, there were 55,622 measles cases and 123 associated deaths across the country.
We are in the midst of the worst outbreak since then, with the number of confirmed cases this year
Results showed patients who received erector spinae plane block consumed fewer opioids on postoperative day 0 after minimally invasive transforaminal lumbar interbody fusion.
“From an anesthetic standpoint, relative to controls, patients [who received erector spinae plane block] are using significantly fewer opioids on postoperative day 0,” Douglas S. Wetmore, MD, anesthesiologist at Hospital for Special Surgery, told Healio about results presented at the Society for Minimally Invasive Spine Surgery Annual Forum. “They have a cleaner and smoother recovery on postoperative day 0 if they get
SAN DIEGO — As demand increases for anti-amyloid therapy that can slow the progression of Alzheimer’s disease, it will be crucial for healthcare systems to find more efficient ways to review referrals for treatment, according to a presenter.
For example, Sutter Health, a nonprofit integrated healthcare system, has implemented a review board that evaluates cases for general neurologists so they can provide these treatments, Armen Moughamian, MD, PhD, chief of memory at Sutter Health, said at the American Neurological Association’s 151st Annual Meeting.
Key barriers to managing demand for the
At current standard of care, less than half of women with recurrent platinum sensitive ovarian cancer who have had prior treatment with poly(ADP-ribose) polymerase inhibitors respond to subsequent therapy.
Phase 1 data presented at European Society for Medical Oncology Congress showed treatment with sofetabart mipitecan (Eli Lilly and Company), a folate receptor alpha-targeting antibody drug conjugate, plus bevacizumab (Avastin, Genentech) resulted in a confirmed overall response rate of nearly 80%.
“Women with platinum sensitive ovarian cancer have mainly one option when their cancer recurs,
HHS has taken action to expand access to six peptides that were key in a controversial meeting this summer.
The interim enforcement policy states that, based on the Pharmacy Compounding Advisory Committee (PCAC) meeting that took place in July, “HHS believes that there is significant interest in the use of these peptides in compounding.” So, in an effort “to expand and improve patient access while FDA reviews these substances,” HHS will not take action against physicians, state-licensed pharmacies or federal facilities compounding a drug using the following bulk drug substances on the 503A
FDA data illustrate patients’ experiences with visual and clarity issues with IOLs, according to a retrospective observational analysis published in Journal of Refractive Surgery.
Idan Hecht, MD, of the department of ophthalmology at Mayo Clinic, and colleagues explored data from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database to compare visual symptoms and optical clarity concerns across IOL types.
“Although the MAUDE database does not inform on device usage and therefore cannot provide incidence estimates, the reports can help characterize the nature and patterns
Individuals with ADHD experienced increased risk for all-cause and cause-specific mortality, including from suicide, injury and natural causes, according to a systematic review and meta-analysis published in JAMA Network Open.
Notably, ADHD medication reduced adverse outcomes among participants, underscoring the importance of timely diagnosis and treatment, researchers found.
“We know that ADHD can have a significant impact on people’s lives, extending beyond its core symptoms to mental health, physical health and social well-being,” Lucy Corrigan, BSc, research assistant in the department of